IMMUPHARMA PLC — Board/Management Information 2018

Sep 19, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1740B

Immupharma PLC

19 September 2018

19 September 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

Appointment of Joint Brokers

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They will work in conjunction with Northland Capital Partners who are the Company's NOMAD and broker.

Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma said:

"As per our recently announced corporate update, we are looking forward with confidence to the future progress of ImmuPharma. As part of our continued proactive investor relations strategy, we also look forward to working with Stanford Capital and SI Capital as part of our corporate advisory team."

For further information please contact:

ImmuPharma plc (www.immupharma.co.uk)	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
Northland Capital Partners Limited (NOMAD & Joint Broker) David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking Stanford Capital Partners (Joint Broker) Patrick Claridge Chris Coleman SI Capital (Joint Broker)                                                                      Nick Emerson	+44 (0)20 3861 6625 +44 (0) 20 3815 8880 +44 (0) 1483 413500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPFKFDDABKDQCD